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Subacute sclerosing panencephalitis (SSPE) is a rare
disease caused by defective measles vaccination or
virus in children [1] .  The typical  neurologic
manifestations of this disease include subtle changes
in mental status at initial presentation, followed by
myoclonus, motor incoordination, visual defect, and
speech impairment. The disease then progresses to
stupor, coma, and death [2,3]. The average clinical
course is 1 to 3 years with rare spontaneous remissions
[4,5]. Numerous therapeutic agents have been reported
to be beneficial in the treatment of SSPE [6]. However,
recent reports have suggested that combination
treatment with inosiplex and interferon-α (IFN-α) may
be most effective in slowing the progression of SSPE
[7–9].
We report a case of SSPE with typical histopatho-
logic findings on brain biopsy [10], who received
intraventricular IFN-α and oral inosiplex combination
treatment [7]. We also discuss the clinical response.
CASE PRESENTATION
A 15-year-old boy had enjoyed good health until the
age of 14, when he began to experience a progressive
tic-like symptom, strange behavior, and poor
performance at school, which forced him to drop out
of school. Initially, he was suspected of having a tic
disorder, and he was treated at a psychiatric clinic for
6 months, when his mental status and periodic
involuntary jerky movements began to deteriorate. He
was referred to the Department of Neurology of
Kaohsiung Medical University Hospital on May 22,
2001. His medical history included uncomplicated
measles infection at age 3 and unremarkable measles-
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mumps-rubella (MMR) vaccination (age at vaccina-
tion unknown).
On admission, neurologic examination revealed
s e v e r e  g e n e r a l  d y s t o n i a  w i t h  i n t e r m i t t e n t
asynchronized myoclonic jerks and a stuporous state.
Deep tendon reflexes were symmetrically decreased
bilaterally, although bilateral extensor plantar
responses were present. An electroencephalogram
(EEG) revealed a diffuse periodic complex with giant
slow waves mixed with episodic sharp waves lasting
from 0.5 to 1 second. The interval between each complex
was about 1 to 3 seconds (Figure 1A). Video-EEG
monitoring revealed a constant relationship between
Figure 1. (A) Initial stage electroencephalogram (EEG) on
admission: continuous diffuse periodic complex with giant slow
waves (arrows) mixed with episodic sharp waves (arrowheads)
lasting for 0.5–1 second. (B) Myoclonic stage EEG showed a
periodic sharp wave complex with a constant relationship to each
generalized myoclonic jerk (arrows). The period between each
myoclonic jerk varied from 9–10 seconds to 6–7 seconds as time
elapsed.
the periodic sharp wave complex and myoclonic jerk,
a finding unique to the EEG pattern of stage II SSPE,
the myoclonic stage [1]. This EEG pattern varied its
period as time elapsed (Figure 1B).
Laboratory results were all within normal limits
except for cerebrospinal fluid (CSF) studies, which
revealed elevated immunoglobulin (Ig) G (> 20% of
total protein; 14.1/57 mg/dL), slight pleocytosis
(12 monocytes/mm3), mild increase in protein
concentration (57 mg/dL), and normal glucose
CSF/serum ratio (74/102 mg/dL). The measles IgG
antibody titer was 1:8 in CSF and 1:128 in serum.
Rubella-specific IgG antibody study was also positive
in both serum and CSF. Brain magnetic resonance
imaging demonstrated high signal intensity in the left
parietal-occipital lobe and right occipital lobe on T2-
weighted image and fluid-attenuated inversion-
recovery study. Both cortex and subcortical white
matter were involved (Figure 2). Single-photon
emission computerized tomography showed
significant cold defects in the same areas.
Based on the specific EEG findings, clinical
manifestations, and measles-specific IgG antibody in the
CSF, the diagnosis of SSPE was confirmed. Combined
treatment using oral inosiplex and intraventricular
injection of IFN-α was started after informed consent
was obtained from the patient’s family. The patient
underwent brain biopsy with Ommaya reservoir
implantation. Histopathologic examination of brain tissue
revealed mild neuronal degeneration with the presence
of intranuclear viral inclusion bodies in pyramidal cells
and perivascular cuffing. Typical rod-shaped glial cells
and eosinophilic Cowdry A inclusion bodies were also
found (Figure 3).
Oral administration of inosiplex (100 mg/kg/day
in two divided doses) and intraventricular IFN-α
injection (104 U/m2 with daily increments up to
106 U/m2 ) were started on June 8, 2001, and continued
for 6 weeks in one course according to the therapeutic
regimen of Yalaz et al [10]. The neurologic disability
index (NDI), designed for SSPE by Dyken et al [7], and
the SSPE staging system, described by Risk and Haddad
[11], were used in clinical evaluation. In this case, the
clinical course rapidly progressed from stage IIa to
IIIb in the month before inosiplex and intraventricular
IFN-α were administered. One month after the
administration of these two drugs, the patient’s
condition had stabilized. The NDI decreased from a
pretreatment score of 50% to a post-treatment score of
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SSPE case in Taiwan over the last 10 years [12]. Ours is
the first SSPE case to be reported in southern Taiwan.
When we compared our case with previously
reported cases, we found two interesting differences.
First, our patient tested positive for rubella-specific
IgG antibody in both serum and CSF studies, which
led us to consider the possibility of concomitant rubella
virus until the results of the brain biopsy were available.
Since these two viral diseases have similar clinical
courses, it is difficult to make a differential diagnosis
between SSPE and progressive rubella panencephalitis
(PRP) without histopathologic confirmation [13]. In
this case, brain biopsy showed mild neuronal
degeneration with staining of Cowdry A intranuclear
inclusion bodies and intracytoplasmic inclusion bodies,
which is characteristic of SSPE (Figure 3) [13]. PRP is
rarely associated with stained inclusion bodies [14].
Second, the measles-specific IgG antibody titer was
elevated after combination treatment with oral
inosiplex and intraventricular IFN-α. This elevation
may have been caused by INF-α activation of the
immune system, which reacts against the defective
measles virus by increasing measles-specific IgG
antibodies, or by the subacute infection course of SSPE
[15].
SSPE usual ly  has  a  fatal  course ,  and the
pathophysiology of remissions or improvements
brought about by different therapies remains unclear.
IFN may have antiviral effects and may modify the
immune response. Low levels of endogenous IFN in
the central nervous system [16] and resistance of the
virus to IFN [17] have been reported. Therefore, it
seems reasonable that exogenous IFN could be used to
treat SSPE. According to a follow-up study of SSPE
patients by Anlar et al [5], combination treatment with
oral inosiplex and intraventricular IFN-α injection
increases survival and gives rise to remission or
stabilization, especially in slowly progressive cases.
Fortunately, our case improved and stabilized in
response to combination treatment.
The initial presentations of SSPE are usually subtle
cognitive dysfunction and disorganized behavior,
problems that are usually the first to make patients
visit  neurologic or  psychiatric  cl inics .  Early
identification of this illness might be helpful in the
treatment and prevention of the associated rapid
deterioration. It is necessary for physicians to
understand the early manifestations in order to begin
active treatment as quickly as possible.
Figure 2. Brain magnetic resonance image: fluid-attenuated
inversion-recovery study revealed a high signal intensity lesion
in the left parietal-occipital and right occipital lobe; both cortex
and subcortical white matter were involved.
Figure 3. Brain biopsy of the right frontal cortex during Ommaya
implantation showed: Cowdry A inclusion bodies (yellow arrows);
perivascular cuffing with lymphocyte infiltration (green arrow);
and rod-shaped glial cells (red arrows). (Hematoxylin & eosin,
10 × 40)
45%. Repeat CSF studies were carried out and a sec-
ond course of intraventricular IFN-α was initiated 2
months later. The patient’s clinical condition was un-
changed after 8 months of follow-up. Although the
NDI remained at 45% after the second course of
treatment, the measles-specific IgG antibody titer had
risen from 1:8 to 1:32, with no elevation in the titers of
other anti-viral antibodies.
DISCUSSION
SSPE is relatively rare in developed countries, but its
incidence remains high in developing countries such
as India and countries in the Middle East [6,10,11]. To
our knowledge, there has only been one reported
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